Sign in or create an account to add this stock to your watchlist.
About Myriad Genetics (NASDAQ:MYGN)
Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer. In addition, the company offers myPath Melanoma, a RNA expression test for diagnosing melanoma; myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency; and GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. Further, it provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600
Debt
Debt-to-Equity Ratio0.07
Current Ratio3.52
Quick Ratio3.16
Price-To-Earnings
Trailing P/E Ratio33.65
Forward P/E Ratio29.44
P/E Growth3.81
Sales & Book Value
Annual Sales$771.40 million
Price / Sales3.20
Cash Flow$1.7683 per share
Price / Cash19.98
Book Value$11.42 per share
Price / Book3.09
Profitability
EPS (Most Recent Fiscal Year)$1.05
Net Income$21.80 million
Net Margins17.67%
Return on Equity9.52%
Return on Assets6.82%
Miscellaneous
Employees2,400
Outstanding Shares69,910,000
Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions
What is Myriad Genetics' stock symbol?
Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."
How were Myriad Genetics' earnings last quarter?
Myriad Genetics (NASDAQ:MYGN) posted its earnings results on Tuesday, May, 8th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.04. The business had revenue of $193.50 million for the quarter, compared to the consensus estimate of $188.22 million. Myriad Genetics had a net margin of 17.67% and a return on equity of 9.52%. The company's revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.27 EPS. View Myriad Genetics' Earnings History.
What guidance has Myriad Genetics issued on next quarter's earnings?
Myriad Genetics updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $1.19-1.21 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.15. The company issued revenue guidance of $771-773 million, compared to the consensus revenue estimate of $770.43 million.
What price target have analysts set for MYGN?
11 Wall Street analysts have issued 1 year price objectives for Myriad Genetics' stock. Their predictions range from $16.00 to $45.00. On average, they expect Myriad Genetics' stock price to reach $30.9091 in the next year. View Analyst Ratings for Myriad Genetics.
What are Wall Street analysts saying about Myriad Genetics stock?
Here are some recent quotes from research analysts about Myriad Genetics stock:
- 1. According to Zacks Investment Research, "Despite weakness in Hereditary Cancer testing revenues, Myriad Genetics exited the third quarter of fiscal 2018 on a promising note. The company observed strong growth in GeneSight, Vectra DA and Prolaris testing revenues. Also, Hereditary Cancer volumes expansion was impressive. Furthermore, we are upbeat about the company seeing growth in new product volumes and success of its Elevate 2020 program. Moreover, the company's latest receipt of manufacturing and marketing approval for its BRACAnalysis Diagnostic System in Japan, buoys optimism. Further, the raised FY18 guidance instills confidence in investors. Accordingly, over the past three months, the company has outperformed its industry. However, the decline in Hereditary cancer testing revenues due to price reductions in long-term contracts, raises a concern. Additionally, currency fluctuations and stiff competition are major headwinds." (5/18/2018)
- 2. Stephens analysts commented, "We initiate coverage of Nightstar Therapeutics (NITE) with a Buy rating (PT$40), on the market opportunity likely addressed by NSR- REP1 in choroideremia (CHM). Choroideremia is a rare, inherited degenerative disease of the retina that typically has onsets in childhood or early adolescence. Patients then progress to reach legal or complete blindness in their 40s or 50s. There are currently no FDA-approved disease-modifying therapies for CHM. Nightstar’s lead asset, AAV-based gene therapy, NSR-REP1, is due to enter the 140-patient pivotal phase III STAR trial in 1H18 for the treatment of CHM. With the Lancet-published phase I/II data for NSR-REP1 in CHM, and subsequent updates from the multi-center program, Nightstar has been able to show that all NSR-REP1- treated patients who received the therapeutic dose were able to maintain vision to 5 years after treatment." (1/3/2018)
Who are some of Myriad Genetics' key competitors?
Some companies that are related to Myriad Genetics include Neogen (NEOG), Immunomedics (IMMU), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), New England Nuclear (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), Vermillion (VRML), Akers Biosciences (AKER) and ImmuCell (ICCC).
Who are Myriad Genetics' key executives?
Myriad Genetics' management team includes the folowing people:
- Mr. Mark Christopher Capone, Pres, CEO & Director (Age 56)
- Mr. R. Bryan Riggsbee, CFO & Treasurer (Age 47)
- Dr. Jerry S. Lanchbury Ph.D., Chief Scientific Officer (Age 59)
- Mr. Richard M. Marsh Esq., Exec. VP, Gen. Counsel & Sec. (Age 60)
- Mr. Alexander Ford, Pres of Myriad Genetic Laboratories, Inc. (Age 51)
Has Myriad Genetics been receiving favorable news coverage?
Media headlines about MYGN stock have been trending very positive this week, according to Accern. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Myriad Genetics earned a news impact score of 0.51 on Accern's scale. They also assigned headlines about the company an impact score of 47.26 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Myriad Genetics' major shareholders?
Myriad Genetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.88%), Baillie Gifford & Co. (13.69%), Dimensional Fund Advisors LP (5.03%), Thrivent Financial for Lutherans (4.08%), Frontier Capital Management Co. LLC (2.88%) and Northern Trust Corp (2.51%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, Heinrich Dreismann, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.
Which institutional investors are selling Myriad Genetics stock?
MYGN stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Millennium Management LLC, Caisse DE Depot ET Placement DU Quebec, Alambic Investment Management L.P., Baillie Gifford & Co., California Public Employees Retirement System, Pinnacle Associates Ltd. and Disciplined Growth Investors Inc. MN. Company insiders that have sold Myriad Genetics company stock in the last year include Alexander Ford, Gary A King, Heinrich Dreismann, John T Henderson, Richard M Marsh and Walter Phd Gilbert. View Insider Buying and Selling for Myriad Genetics.
Which institutional investors are buying Myriad Genetics stock?
MYGN stock was bought by a variety of institutional investors in the last quarter, including Sensato Investors LLC, Matarin Capital Management LLC, BlackRock Inc., Allianz Asset Management GmbH, UBS Group AG, JPMorgan Chase & Co., Northern Trust Corp and Federated Investors Inc. PA. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade. View Insider Buying and Selling for Myriad Genetics.
How do I buy shares of Myriad Genetics?
Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myriad Genetics' stock price today?
One share of MYGN stock can currently be purchased for approximately $35.35.
How big of a company is Myriad Genetics?
Myriad Genetics has a market capitalization of $2.47 billion and generates $771.40 million in revenue each year. The company earns $21.80 million in net income (profit) each year or $1.05 on an earnings per share basis. Myriad Genetics employs 2,400 workers across the globe.
How can I contact Myriad Genetics?
Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]
MarketBeat Community Rating for Myriad Genetics (MYGN)
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Myriad Genetics (NASDAQ:MYGN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Myriad Genetics in the last 12 months. Their average twelve-month price target is $30.9091, suggesting that the stock has a possible downside of 12.51%. The high price target for MYGN is $45.00 and the low price target for MYGN is $16.00. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 1.91 | 1.90 |
| Ratings Breakdown: | 2 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $30.9091 | $30.4545 | $30.4545 | $26.5556 |
| Price Target Upside: | 12.51% downside | 2.89% upside | 9.71% downside | 14.75% downside |
Myriad Genetics (NASDAQ:MYGN) Consensus Price Target History
Myriad Genetics (NASDAQ:MYGN) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Myriad Genetics (NASDAQ:MYGN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Myriad Genetics (NASDAQ MYGN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.70%
Myriad Genetics (NASDAQ MYGN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/22/2018 | Richard M Marsh | VP | Sell | 37,654 | $40.25 | $1,515,573.50 | 157,648 |  |
| 1/18/2018 | Gary A King | VP | Sell | 3,120 | $38.12 | $118,934.40 | 125,088 | |
| 1/12/2018 | Richard M Marsh | VP | Sell | 13,759 | $36.25 | $498,763.75 | 136,385 | |
| 12/14/2017 | Walter Phd Gilbert | Director | Sell | 7,500 | $33.19 | $248,925.00 | | |
| 12/11/2017 | Heinrich Dreismann | Director | Sell | 6,000 | $33.50 | $201,000.00 | 33,743 | |
| 11/13/2017 | Alexander Ford | Insider | Sell | 3,031 | $31.64 | $95,900.84 | | |
| 9/1/2017 | John T Henderson | Director | Sell | 30,000 | $30.30 | $909,000.00 | 52,524 | |
| 2/23/2017 | John T Henderson | Director | Buy | 6,000 | $18.66 | $111,960.00 | 38,524 | |
| 9/12/2016 | John T Henderson | Director | Sell | 30,000 | $20.49 | $614,700.00 | 49,493 | |
| 8/19/2016 | Mark Christopher Capone | Insider | Buy | 10,000 | $21.24 | $212,400.00 | 146,026 | |
| 8/12/2016 | Ralph L Mcdade | Insider | Buy | 1,000 | $21.49 | $21,490.00 | 56,720 | |
| 6/21/2016 | Alexander Ford | Insider | Sell | 18,637 | $30.87 | $575,324.19 | 40,122 | |
| 4/6/2016 | Gary A King | VP | Sell | 15,000 | $39.03 | $585,450.00 | 95,640 | |
| 4/1/2016 | Gary A King | VP | Sell | 15,000 | $38.12 | $571,800.00 | 95,640 | |
| 12/11/2015 | Walter Phd Gilbert | Director | Sell | 5,000 | $42.23 | $211,150.00 | 12,500 | |
| 12/8/2015 | S. Louise Phanstiel | Director | Sell | 5,000 | $44.00 | $220,000.00 | 8,500 | |
| 11/5/2015 | Heinrich Dreismann | Director | Sell | 60,000 | $44.44 | $2,666,400.00 | 10,000 | |
| 11/4/2015 | Richard M. Marsh | VP | Sell | 35,000 | $44.50 | $1,557,500.00 | 68,384 | |
| 10/28/2015 | Gary A. King | VP | Sell | 10,000 | $42.82 | $428,200.00 | 80,573 | |
| 10/28/2015 | Jerry S. Lanchbury | insider | Sell | 50,962 | $41.86 | $2,133,269.32 | 70,737 | |
| 10/27/2015 | Jerry S. Lanchbury | insider | Sell | 24,767 | $41.80 | $1,035,260.60 | 70,737 | |
| 9/17/2015 | Jerry S. Lanchbury | insider | Sell | 60,270 | $39.89 | $2,404,170.30 | 70,737 | |
| 9/16/2015 | Richard M. Marsh | VP | Sell | 35,000 | $41.25 | $1,443,750.00 | 67,543 | |
| 9/14/2015 | Gary A. King | VP | Sell | 14,562 | $39.41 | $573,888.42 | 51,473 | |
| 9/3/2015 | Gary A. King | VP | Sell | 25,438 | $39.41 | $1,002,511.58 | 51,473 | |
| 9/2/2015 | Gary A. King | VP | Sell | 15,000 | $38.23 | $573,450.00 | 51,473 | |
| 8/28/2015 | Gary A. King | VP | Sell | 30,000 | $35.73 | $1,071,900.00 | 51,473 | |
| 11/3/2014 | Gary A King | VP | Sell | 6,568 | $39.95 | $262,391.60 | | |
| 9/30/2014 | James S Evans | CFO | Sell | 21,850 | $38.99 | $851,931.50 | | |
| 9/24/2014 | James S Evans | CFO | Sell | 8,790 | $37.98 | $333,844.20 | | |
| 9/23/2014 | James S Evans | CFO | Sell | 110,463 | $37.89 | $4,185,443.07 | | |
| 7/14/2014 | Peter D Meldrum | Insider | Sell | 24,000 | $39.50 | $948,000.00 | | |
| 6/5/2014 | John T Henderson | Director | Sell | 5,000 | $35.70 | $178,500.00 | | |
| 5/9/2014 | Ronald Rogers | VP | Sell | 12,500 | $36.01 | $450,125.00 | | |
| 4/30/2014 | Richard Marsh | VP | Sell | 30,000 | $41.80 | $1,254,000.00 | 18,285 | |
| 4/23/2014 | Richard Marsh | VP | Sell | 31,516 | $39.80 | $1,254,336.80 | 18,285 | |
| 4/16/2014 | Richard Marsh | VP | Sell | 28,484 | $39.80 | $1,133,663.20 | 18,285 | |
| 4/7/2014 | Jayne Hart | VP | Sell | 79,000 | $40.90 | $3,231,100.00 | 930 | |
| 4/2/2014 | James Evans | CFO | Sell | 80,000 | $40.00 | $3,200,000.00 | 47,609 | |
| 4/2/2014 | Peter Meldrum | Insider | Sell | 55,000 | $39.57 | $2,176,350.00 | 15,084 | |
| 3/19/2014 | Peter Meldrum | Insider | Sell | 55,000 | $37.00 | $2,035,000.00 | 26,084 | |
| 3/17/2014 | Peter Meldrum | Insider | Sell | 55,000 | $35.15 | $1,933,250.00 | 26,084 | |
| 3/12/2014 | Richard Marsh | VP | Sell | 50,000 | $34.37 | $1,718,500.00 | 17,165 | |
| 2/26/2014 | Walter Phd Gilbert | Director | Sell | 30,000 | $37.58 | $1,127,400.00 | | |
| 2/25/2014 | Mark Christopher Capone | Insider | Sell | 95,250 | $37.83 | $3,603,307.50 | 48,268 | |
| 2/24/2014 | Gary King | VP | Sell | 20,000 | $38.00 | $760,000.00 | 2,949 | |
| 2/20/2014 | James Evans | CFO | Sell | 30,000 | $36.01 | $1,080,300.00 | 47,609 | |
| 2/20/2014 | Robert Gardner Harrison | Insider | Sell | 17,554 | $36.22 | $635,805.88 | 324 | |
| 2/19/2014 | Richard Marsh | VP | Sell | 34,676 | $34.71 | $1,203,603.96 | 17,165 | |
| 2/19/2014 | Walter Phd Gilbert | Director | Sell | 60,000 | $34.48 | $2,068,800.00 | | |
| 2/18/2014 | Gary King | VP | Sell | 25,000 | $34.74 | $868,500.00 | 2,949 | |
| 2/18/2014 | Heinrich Dreismann | Director | Sell | 30,000 | $35.00 | $1,050,000.00 | | |
| 2/14/2014 | Richard Marsh | VP | Sell | 20,960 | $31.50 | $660,240.00 | 17,165 | |
| 2/12/2014 | Robert Gardner Harrison | Insider | Sell | 13,707 | $30.74 | $421,353.18 | 324 | |
| 2/10/2014 | Mark Christopher Capone | Insider | Sell | 87,500 | $32.07 | $2,806,125.00 | 48,268 | |
| 2/7/2014 | James Evans | CFO | Sell | 35,000 | $33.04 | $1,156,400.00 | 47,609 | |
| 2/5/2014 | Peter Meldrum | Insider | Sell | 123,940 | $31.10 | $3,854,534.00 | 55,656 | |
| 11/8/2013 | James Evans | CFO | Sell | 8,072 | $26.50 | $213,908.00 | 47,177 | |
| 11/8/2013 | Peter Meldrum | Insider | Sell | 31,784 | $26.50 | $842,276.00 | 55,656 | |
| 6/13/2013 | Robert Gardner Harrison | Insider | Sell | 31,498 | $36.17 | $1,139,282.66 | | |
| 5/16/2013 | Mark Christopher Capone | Insider | Sell | 79,999 | $33.23 | $2,658,366.77 | | |
| 5/14/2013 | Peter D Meldrum | Insider | Sell | 15,000 | $34.00 | $510,000.00 | | |
| 5/10/2013 | Heinrich Dreismann | Director | Sell | 30,000 | $31.16 | $934,800.00 | | |
| 5/10/2013 | Peter D Meldrum | Insider | Sell | 75,960 | $31.99 | $2,429,960.40 | | |
| 5/10/2013 | Richard M Marsh | VP | Sell | 48,192 | $33.00 | $1,590,336.00 | | |
| 10/4/2012 | Jerry S Lanchbury | Insider | Sell | 3,900 | $28.50 | $111,150.00 | | |
| 10/3/2012 | Jerry S Lanchbury | Insider | Sell | 3,000 | $28.50 | $85,500.00 | | |
| 9/14/2012 | Peter D Meldrum | Insider | Sell | 20,000 | $27.60 | $552,000.00 | | |
| 9/13/2012 | James S Evans | CFO | Sell | 5,494 | $27.10 | $148,887.40 | | |
(Data available from 1/1/2013 forward)
Myriad Genetics (NASDAQ MYGN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | MYGN ALERT: Rosen Law Firm Reminds Myriad Genetics, Inc. Investors of Important Deadline in Class Action - MYGN
www.prnewswire.com - May 19 at 11:48 AM |
| MYRIAD GENETICS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN
www.prnewswire.com - May 18 at 11:42 PM |
 | Myriad Genetics (MYGN) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 18 at 4:44 PM |
 | Better Buy: Opko Health, Inc. (OPK) vs. Myriad Genetics (MYGN)
www.fool.com - May 18 at 2:40 PM |
 | Myriad Genetics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Possible Breaches of Fiduciary Duty by Officers and Directors
finance.yahoo.com - May 18 at 10:35 AM |
| The Klein Law Firm Notifies Investors of a Class Action on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 17 at 3:28 PM |
| Head to Head Review: Myriad Genetics (MYGN) vs. Vermillion (VRML)
www.americanbankingnews.com - May 17 at 3:23 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Myriad Genetics, Inc. (MYGN) & Lead Plaintiff Deadline: June 19, 2018
finance.yahoo.com - May 17 at 10:58 AM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Myriad Genetics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2018 - MYGN
finance.yahoo.com - May 17 at 10:58 AM |
| Myriad Genetics (MYGN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 17 at 5:29 AM |
| MYGN EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Myriad Genetics, Inc. and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 15 at 3:28 PM |
| Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 15 at 11:05 AM |
| Kessler Topaz Meltzer & Check, LLP Reminds Myriad Genetics, Inc. Investors of Important Deadline in Class Action Lawsuit
finance.yahoo.com - May 15 at 11:05 AM |
| Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 15 at 11:05 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2018 - MYGN
finance.yahoo.com - May 14 at 3:28 PM |
| Jefferies Group Comments on Myriad Genetics' FY2018 Earnings (MYGN)
www.americanbankingnews.com - May 14 at 3:32 AM |
 | SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Myriad Genetics, Inc. (NASDAQ: MYGN) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
feeds.benzinga.com - May 13 at 11:09 PM |
| EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. – MYGN
finance.yahoo.com - May 12 at 11:13 AM |
 | MYRIAD GENETICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in ...
www.businesswire.com - May 12 at 11:13 AM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN
feeds.benzinga.com - May 12 at 9:25 AM |
| Myriad Genetics (MYGN) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - May 11 at 7:50 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Myriad Genetics, Inc. (MYGN) & Lead Plaintiff Deadline - June 19, 2018
finance.yahoo.com - May 11 at 3:37 PM |
| The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 11 at 3:37 PM |
| PAWAR LAW: Important June 19, 2018 Lead Plaintiff Deadline in Myriad Genetics, Inc. Class Action - MYGN
finance.yahoo.com - May 11 at 10:34 AM |
| MYRIAD GENETICS, INC. INVESTOR UPDATE: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of shareholders of Myriad Genetics, Inc.
finance.yahoo.com - May 11 at 10:34 AM |
| Is Myriad Genetics Inc (NASDAQ:MYGN) A Financially Strong Company?
finance.yahoo.com - May 11 at 10:34 AM |
| MYGN EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Myriad Genetics, Inc. and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 10 at 3:28 PM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Myriad Genetics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 10 at 11:04 AM |
| Important Deadline Notice for Myriad Genetics, Inc. Shareholders - MYGN
finance.yahoo.com - May 10 at 11:04 AM |
| INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 10 at 11:04 AM |
| Myriad Genetics Sees Unusually High Options Volume (MYGN)
www.americanbankingnews.com - May 10 at 8:02 AM |
| Myriad Genetics (MYGN) Forecasted to Post FY2018 Earnings of $1.21 Per Share
www.americanbankingnews.com - May 10 at 7:55 AM |
| BTIG Research Analysts Give Myriad Genetics (MYGN) a $42.00 Price Target
www.americanbankingnews.com - May 9 at 5:12 PM |
| Myriad Genetics (MYGN) PT Raised to $35.00 at Morgan Stanley
www.americanbankingnews.com - May 9 at 4:43 PM |
 | The Klein Law Firm Announces a Class Action Filed on Behalf of Myriad Genetics, Inc. Shareholders and a Lead ...
globenewswire.com - May 9 at 3:31 PM |
| The Klein Law Firm Announces a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a ...
www.businesswire.com - May 9 at 3:31 PM |
 | MYRIAD GENETICS, INC.
www.streetinsider.com - May 9 at 3:31 PM |
 | BRIEF-Myriad Genetics Reports Q3 GAAP Earnings Per Share $0.16
www.reuters.com - May 9 at 3:31 PM |
 | Myriad Genetics, Inc. 2018 Q3 - Results - Earnings Call Slides
seekingalpha.com - May 9 at 3:31 PM |
| Myriad Genetics Spikes On Better-Than-Expected Q3 Print
finance.yahoo.com - May 9 at 9:57 AM |
 | Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q3
www.zacks.com - May 9 at 9:57 AM |
| The Klein Law Firm Announces a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 9 at 9:57 AM |
| Edited Transcript of MYGN earnings conference call or presentation 8-May-18 11:30am GMT
finance.yahoo.com - May 9 at 9:57 AM |
| Deadline Alert for Myriad Genetics, Inc. Shareholders in Class Action Lawsuit - MYGN
finance.yahoo.com - May 9 at 9:57 AM |
 | MYGN Makes Bullish Cross Above Critical Moving Average
www.nasdaq.com - May 8 at 3:25 PM |
| Myriad Genetics (MYGN) Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 3:25 PM |
| The Klein Law Firm Announces a Class Action Filed on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 8 at 3:25 PM |
| IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 8 at 3:25 PM |
| Myriad Genetics Inc. Q1 adjusted earnings Beat Estimates
www.nasdaq.com - May 8 at 10:33 AM |
| Which Anti-Depressant is Right for You? Your DNA Can Shed Some Light
finance.yahoo.com - May 8 at 10:33 AM |
Myriad Genetics (NASDAQ:MYGN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Myriad Genetics (NASDAQ:MYGN) Income Statement, Balance Sheet and Cash Flow Statement
Myriad Genetics (NASDAQ MYGN) Stock Chart for Monday, May, 21, 2018
Loading chart…
